ArticleDiscover oncology2025
Integrated single-cell and bulk RNA-sequencing data reveal prognosis and therapeutic response in low-grade glioma based on hypoxia-lactylation related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decoding lactylation heterogeneity in glioblastoma: machine learning identifies G6PC3 as a prognostic target.BMC cancer · 2026Article
- snRNA sequencing-based skeletal muscle analysis of Jiangquan black pigs with different average daily growth rates.Scientific reports · 2026Article
- Molecular mechanisms and clinical significance of the glioma metabolic-immune axis: a comprehensive review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe prognosis of low-grade glioma (LGG) exhibits significant heterogeneity, and the optimal management strategy remains controversial. Therefore, identifying biomarkers associated with glioma prognosis is necessary.
methodsHub genes were identified and a prognostic risk signature was constructed in the TCGA cohort using LASSO Cox regression. The predictive significance of this model was assessed and confirmed in the independent CGGA cohort. Single-cell transcriptional profiling characterized the hub gene expression patterns across cell types.
resultsWe screened four hub genes (SERPINE1, KIF2C, SLC16A1, FABP5). Patients were stratified into high- and low-risk groups using this model. The high-risk group had significantly lower survival rates in both TCGA and CGGA cohorts. The model demonstrated strong predictive power (1/2/3-year AUCs: 0.85/0.85/0.83 in TCGA; 0.73/0.71 for 2/3 years in CGGA). Functionally, the high-risk group exhibited activation of pro-tumorigenic pathways, showed higher levels of immune infiltration across multiple lymphocyte and myeloid subsets, and demonstrated higher sensitivity to drugs such as AZD5582 and AZD8055, evidenced by significantly lower IC50 values. At the single-cell level, FABP5 was highly expressed in myeloid cells, and FABP5 + tumor-associated macrophages (TAMs) were enriched in lipid metabolism and antigen presentation pathways. Pseudotime analysis suggested increasing FABP5 expression during TAMs differentiation.
conclusionsThe constructed 4-gene hypoxia-lactylation prognostic model can effectively predict survival risk in LGG patients. The high-risk group is characterized by activation of pro-tumorigenic pathways, high immune infiltration, and sensitivity to specific targeted drugs. FABP5 + TAMs participate in LGG progression by regulating lipid metabolism and inflammatory responses, representing a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.